{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:09:57Z","timestamp":1792271397480,"version":"4.4.0"},"reference-count":6,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>\n                    A 64-year-old man with metachronous metastatic urothelial carcinoma originating from the right renal pelvis underwent nectin-4\u2013targeted [\n                    <jats:sup>68<\/jats:sup>\n                    Ga]Ga-NECT-224 PET\/CT prior to initiation of nectin-4\u2013targeted antibody-drug conjugate (ADC) therapy with enfortumab-vedotin (PADCEV), in combination with pembrolizumab. A CT follow-up after 3 months of ADC therapy showed a progressive adrenal metastasis. Subsequent [\n                    <jats:sup>68<\/jats:sup>\n                    Ga]Ga-NECT-224 PET\/CT restaging revealed multiple new lesions with intense nectin-4 expression. This case illustrates the potential of [\n                    <jats:sup>68<\/jats:sup>\n                    Ga]Ga-NECT-224 PET\/CT to visualize heterogeneous nectin-4 expression, its potential in therapy guidance, and highlights the need for theranostic strategies in patients retaining target expression despite cytotoxic therapy resistance.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006528","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T13:00:56Z","timestamp":1780923656000},"page":"732-734","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["[68Ga]Ga-NECT-224 PET\/CT Shows Increasing Nectin-4 Expression in Progressive Urothelial Carcinoma Under ADC-Therapy With Enfortumab-Vedotin"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3601-0924","authenticated-orcid":false,"given":"Sebastian","family":"Hober\u00fcck","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severine","family":"Banek","sequence":"additional","affiliation":[{"name":"Department of Urology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Kr\u00f6nke","sequence":"additional","affiliation":[{"name":"Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pretze","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Brandt","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Kopka","sequence":"additional","affiliation":[{"name":"Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf"},{"name":"School of Science, Faculty of Chemistry and Food Chemistry, TUD Dresden University of Technology"},{"name":"German Cancer Consortium (DKTK), Partner Site Dresden"},{"name":"National Center for Tumor Diseases (NCT), NCT\/UCC Dresden, A Partnership Between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Trommer","sequence":"additional","affiliation":[{"name":"Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Urology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph A.","family":"Bundschuh","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"R1-20260702","doi-asserted-by":"crossref","first-page":"21962","DOI":"10.1021\/acs.jmedchem.5c02371","article-title":"\u201cPrecision on two wheels\u201d\u2500structural refinement of 64Cu- and 68Ga-labeled bicyclic peptides targeting nectin-4 for improved tumor imaging: from preclinical development to first-in-human application","volume":"68","author":"Kr\u00f6nke","year":"2025","journal-title":"J Med Chem"},{"key":"R2-20260702","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance","volume":"29","author":"Kl\u00fcmper","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R3-20260702","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"R4-20260702","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"R5-20260702","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1158\/1078-0432.CCR-23-0609","article-title":"First-in-human study of the radioligand 68Ga-N188 targeting nectin-4 for PET\/CT imaging of advanced urothelial carcinoma","volume":"29","author":"Duan","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R6-20260702","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/bju.16901","article-title":"Staging metastatic urothelial cancer with Nectin-4 imaging using Gallium-68-N188 PET\/CT","volume":"137","author":"Miederer","year":"2026","journal-title":"BJU Int"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006528","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:10:38Z","timestamp":1783023038000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":6,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006528","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"2026-02-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}